Thelansis

For years, the United States and the United Kingdom have stood on opposite ends of the drug pricing spectrum. The US has historically allowed manufacturers to set list prices with relatively few constraints, while the UK’s NHS relies on strict cost effectiveness evaluations through NICE. So when news broke that both countries were exploring a coordinated framework on drug pricing, it immediately caught the attention of the biopharma world. This isn’t just another bilateral agreement. It signals a shift in how major markets might negotiate access, affordability, and innovation—all at once. Let’s break down what this deal is really about, why it matters, and how it could reshape global pricing norms. So, What Exactly Is the US-UK Drug Pricing Deal? At its core, the agreement aims to: Increase transparency around how drug prices are set Share horizon-scanning intelligence for pipeline product Align approaches to value-based assessments and health-technolog...

Japan has quietly turned its HTA framework into one of the most influential, but often misunderstood, pricing systems in major markets. Since formal cost-effectiveness evaluation became part of the NHI price-setting process in 2019, the country has refined its approach almost every year. The 2024-25 policy cycle marks another step in that evolution, with changes that will matter to anyone planning global launches over the next two to three years. For companies preparing for Japan, the question is no longer “ Will HTA affect our launch? ” It’s “ How early do we start shaping our value story so the HTA process doesn’t dilute our price once we’re on the market? ” What Has Actually Changed by 2025? A few updates drive most of the practical impact: 1. Cost-effectiveness evaluation is now routine in defined situations Japan continues to require manufacturers to submit health-economic analyses when list prices are high, premiums are involved, or comparator uncertainty is high. The...

Introduction: A global biopharma company preparing to advance towards asset commercialisation approached Thelansis with a clear priority that they wanted to enter multiple markets with confidence that their clinical evidence, pricing expectations, and value communication would withstand payer scrutiny. The therapy showed strong early promise, but the success in Phase 3 does not automatically translate into smooth reimbursement pathways, especially in regions where HTA bodies demand tight alignment between clinical value, real-world relevance, and economic justification. Over the past decade, Thelansis has supported companies in similar transitions by helping them understand how payers think, what evidence resonates, and where access bottlenecks typically arise. Problem Statement: The client faced three immediate challenges: Uncertainty around payer expectations across the U.S., EU5, Japan, and selected emerging markets, particularly in unmet need, differentiation,...